Stone formation was investigated in 162 male and female Sprague-Dawley rats (96 males and 66 females) following a portacaval shunt and in 58 sham-operated rats which served as controls (31 males and 27 females). 70.8% male and only 7.5% female shunted rats developed urolithiasis. All stones of sufficient size were analyzed. The majority of stones in shunt-operated rats were made of potassium hydrogen urate (23/41), 10 rats had struvite stones without urinary tract infection, the remaining 8 rats had composite stones. Analysis of all stone-bearing control animals revealed struvite stones (6/6). Postoperatively, the rats developed polyuria, elevated potassium and uric acid excretion (all sex dependent). Urnary pH levels did not change significantly. Organ changes (atrophy of the liver, the testes and ovaries, hypertrophy of the kidney and the adrenal glands) were significant and differed according to sex. The role of sex hormones and prostaglandins is discussed.

Keywords:
Portacaval shunt, Urolithiasis
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.